Discover
BCAX
Bicara Therapeutics Inc.
28.91
2 x 21.16
2 x 36.97
bid
ask
-
0.78
2.63%
2 @ 04:39 AM
29.03 +0.12 (0.42%)
| Ytd | 71.78% | |
| 1y | 205.60% |
28.78
day range
29.90
8.74
52 week range
29.90
| Open | 29.36 | Prev Close | 29.69 | Low | 28.78 | High | 29.90 | Mkt Cap | 1.90B |
| Vol | 834.56K | Avg Vol | 667.48K | EPS | -2.77 | P/E | N/A | Forward P/E | -7.96 |
| Beta | N/A | Short Ratio | 20.56 | Inst. Own | 104.35% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-11 | 50-d Avg | 22.47 | 200-d Avg | 18.48 | 1yr Est | 31.46 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2026-05-11 | 2026-03 | 0 | N/A | N/A | N/A |
| 2026-03-30 | 2025-12 | 0 | N/A | N/A | N/A |
| 2025-11-10 | 2025-09 | 0 | N/A | -0.12 | -21.82% |
| 2025-11-10 | 2025-09 | 0 | N/A | N/A | N/A |
| 2025-08-12 | 2025-06 | 0 | N/A | N/A | N/A |
| 2025-08-12 | 2025-06 | 0 | N/A | 0.04 | 7.41% |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2026-05-12 | Goldman Sachs | Upgrade | Neutral | Neutral |
| 2026-05-12 | Morgan Stanley | Upgrade | Overweight | Overweight |
| 2026-05-11 | Guggenheim | Upgrade | Buy | |
| 2026-03-31 | Goldman Sachs | Upgrade | Neutral | Neutral |
| 2026-03-31 | Wedbush | Upgrade | Outperform | Outperform |
| 2026-03-31 | Wells Fargo | Upgrade | Equal-Weight | Equal-Weight |
Profile
Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines a clinically validated epidermal growth factor receptor directed monoclonal antibody bound to human transforming growth factor beta for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2024-09-15 | BIOCON LTD. | Beneficial Owner of more than 10% of a Class of Security | 0.00 | Conversion of Exercise of derivative security |
| 2024-09-15 | FIL, LTD. | Beneficial Owner of more than 10% of a Class of Security | 0.00 | Conversion of Exercise of derivative security |
| 2024-09-16 | FLYNN JAMES E | Beneficial Owner of more than 10% of a Class of Security | 0.00 | Purchase |
| 2024-09-15 | FMR LLC | Unknown | 0.00 | Conversion of Exercise of derivative security |
| 2026-05-17 | MAZUMDAR CLAIRE | Chief Executive Officer | 362.15K | Sale |
| 2024-09-15 | MAZUMDAR-SHAW KIRAN | Director and Beneficial Owner of more than 10% of a Class of Security | 0.00 | Conversion of Exercise of derivative security |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-03-30 | RA Capital Management, L.P. | 7.26M | 209.77M | 11.04% |
| 2026-03-30 | T. Rowe Price Investment Management, Inc. | 6.61M | 190.97M | 10.05% |
| 2026-03-30 | Siren, L.L.C. | 5.80M | 167.76M | 8.83% |
| 2026-03-30 | Vestal Point Capital, LP | 5.43M | 156.84M | 8.26% |
| 2026-03-30 | Deep Track Capital, Lp | 4.06M | 117.45M | 6.18% |
| 2026-03-30 | Janus Henderson Group PLC | 3.34M | 96.54M | 5.08% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-03-30 | T. Rowe Price Small-Cap Stock Fund, Inc. | 2.18M | 63.07M | 3.32% |
| 2026-03-30 | VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 1.37M | 39.65M | 2.09% |
| 2026-03-30 | T. Rowe Price Eqy. Fd.s, Inc.-T. Rowe Price Inst. Small-Cap Stock Fd. | 1.20M | 34.59M | 1.82% |
| 2026-03-30 | -Price (T.Rowe) U.S. Small-Cap Core Equity Trust | 1.03M | 29.90M | 1.57% |
| 2026-05-30 | Fidelity Select Portfolios-Select Biotechnology Portfolio | 944.90K | 27.32M | 1.44% |
| 2026-05-30 | SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 781.32K | 22.59M | 1.19% |